Early average change in tumor size in a phase 2 trial: Efficient endpoint or false promise?

Journal of the National Cancer Institute

Volumn 99, Issue 19, 2007, Pages 1422-1423

  Rubinstein, Larry V ^a   Dancey, Janet E ^a   Korn, Edward L ^a   Smith, Malcolm A ^a   Wright, John J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

DRUG EFFECT; DRUG MECHANISM; EDITORIAL; INTERNAL BIAS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZATION; SAMPLE SIZE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; BIOASSAY; DISEASE COURSE; DISEASE FREE SURVIVAL; HUMAN; METHODOLOGY; NEOPLASM; NOTE; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 35148868544     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djm167     Document Type: Editorial

References (6)

1. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007;25:1760-4.
2. Karrison TG, Maitland ML, Stadler WM, Ratain MJ. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small-cell lung cancer. J Natl Cancer Inst 2007;99:1455-61.
3. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 2001;19:265-72.
4. Rubinstein LV, Korn EL, Freidlin B, Hunsberger SA, Ivy SP, Smith MA. Randomized phase 2 design issues and a proposal for phase 2 screening trials. J Clin Oncol 2005;23:7199-206.
5. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.